Back to User profile » Dr Paul J Rowe
Papers published by Dr Paul J Rowe:
Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study
Guilbert TW, Tolcachier A, Fiocchi AG, Katelaris CH, Phipatanakul W, Begin P, de Mir I, Altincatal A, Gall R, Ledanois O, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ
Journal of Asthma and Allergy 2024, 17:143-159
Published Date: 5 March 2024
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study
Guilbert TW, Murphy KR, Hamelmann E, Ross KR, Gupta A, Fiocchi A, Xia C, Gall R, Ledanois O, Radwan A, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2024, 17:81-87
Published Date: 8 February 2024
Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma
Gurnell M, Radwan A, Bachert C, Lugogo N, Cho SH, Nash S, Zhang H, Khan AH, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2024, 17:1-8
Published Date: 16 January 2024
Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
Busse WW, Pavord ID, Siddiqui S, Khan AH, Praestgaard A, Nash S, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2023, 16:411-419
Published Date: 18 April 2023
Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
Maspero JF, Khan AH, Philpott C, Hellings PW, Hopkins C, Wagenmann M, Siddiqui S, Msihid J, Nash S, Chuang CC, Kamat S, Rowe PJ, Deniz Y, Jacob-Nara JA
Journal of Asthma and Allergy 2023, 16:323-332
Published Date: 29 March 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
Corren J, Jackson DJ, Casale TB, Borish L, Rabe KF, Busse WW, Maspero JF, Jackson DJ, Daizadeh N, Altincatal A, Radwan A, Khodzhayev A, Djandji M, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2023, 16:249-260
Published Date: 7 March 2023
Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma
Khan AH, Gray C, Eckert L, Amand C, Maroni J, Wang Z, Jones B, Berni T, Morgan CL, Rowe PJ
Journal of Asthma and Allergy 2022, 15:1639-1644
Published Date: 11 November 2022
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
Hanania NA, Maspero JF, Halpin DM, Jackson DJ, Panettieri RA, Castro M, Domingo C, Daizadeh N, Gall R, Jacob-Nara JA, Ortiz B, Djandji M, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2022, 15:851-854
Published Date: 28 June 2022
Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
Hopkins C, Buchheit KM, Heffler E, Cohen NA, Olze H, Khan AH, Msihid J, Siddiqui S, Nash S, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2022, 15:767-773
Published Date: 7 June 2022
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
Bachert C, Khan AH, Hopkins C, Blaiss MS, Soler ZM, Nash S, Siddiqui S, Praestgaard A, Deniz Y, Rowe PJ, Jacob-Nara JA
Journal of Asthma and Allergy 2022, 15:557-563
Published Date: 4 May 2022
Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma
Price D, Menzies-Gow A, Bachert C, Canonica GW, Kocks J, Khan AH, Ye F, Rowe PJ, Lu Y, Kamat S, Carter V, Voorham J
Journal of Asthma and Allergy 2021, 14:1173-1183
Published Date: 29 September 2021
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
Pavord ID, Siddiqui S, Papi A, Corren J, Sher LD, Bardin P, Langton D, Park HS, Rice MS, Deniz Y, Rowe P, Staudinger HW, Patel N, Ruddy M, Graham NMH, Teper A
Journal of Asthma and Allergy 2020, 13:701-711
Published Date: 16 December 2020